Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial

Next Previous
Trial Profile

A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASSET

Most Recent Events

  • 24 Jul 2019 Results (n=88) published in the Arthritis and Rheumatology.
  • 15 Jun 2019 Results assessing the performance of ACR CRISS, a secondary outcome measure, in ASSET at month 12 presented at the 20th Annual Congress of the European League Against Rheumatism
  • 15 Jun 2019 Primary endpoint (Change from baseline in the modified Rodnan skin score (mRSS) to month 12) has not been met as per results presented at the 20th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top